Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether raltegravir is effective in preventing
progression of relapsing remitting multiple sclerosis as determined by gadolinium- enhanced
MRI.